IL143903A - A medicinal product containing pancovinone for the treatment or prevention of memory impairments - Google Patents
A medicinal product containing pancovinone for the treatment or prevention of memory impairmentsInfo
- Publication number
- IL143903A IL143903A IL14390300A IL14390300A IL143903A IL 143903 A IL143903 A IL 143903A IL 14390300 A IL14390300 A IL 14390300A IL 14390300 A IL14390300 A IL 14390300A IL 143903 A IL143903 A IL 143903A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- phanquinone
- memory
- memory impairment
- suffering
- Prior art date
Links
- VLPADTBFADIFKG-UHFFFAOYSA-N phanquone Chemical compound C1=CN=C2C(=O)C(=O)C3=NC=CC=C3C2=C1 VLPADTBFADIFKG-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 229960003606 phanquinone Drugs 0.000 title claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 33
- 206010027175 memory impairment Diseases 0.000 title claims abstract description 28
- 230000002265 prevention Effects 0.000 title claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 7
- 239000003937 drug carrier Substances 0.000 claims abstract description 7
- 230000028252 learning or memory Effects 0.000 claims abstract 5
- 230000015654 memory Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 25
- 239000000470 constituent Substances 0.000 description 11
- 239000003826 tablet Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 5
- 235000019759 Maize starch Nutrition 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000003340 mental effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 230000006403 short-term memory Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960001021 lactose monohydrate Drugs 0.000 description 3
- 230000007787 long-term memory Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- -1 2-benzyl-2-propyl Chemical group 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- ZZWKZQDOSJAGGF-VRSYWUPDSA-N [(1s,2e,7s,10e,12r,13r,15s)-12-hydroxy-7-methyl-9-oxo-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-15-yl] 2-(dimethylamino)acetate Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](OC(=O)CN(C)C)C[C@H]21 ZZWKZQDOSJAGGF-VRSYWUPDSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 230000006993 memory improvement Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- KRKRAOXTGDJWNI-UHFFFAOYSA-N (2R,4S)-4-Methyl glutamic acid Natural products OC(=O)C(C)CC(N)C(O)=O KRKRAOXTGDJWNI-UHFFFAOYSA-N 0.000 description 1
- ZYFTZMADDQMCNB-UHFFFAOYSA-N 2-aminoethyl carbamate Chemical class NCCOC(N)=O ZYFTZMADDQMCNB-UHFFFAOYSA-N 0.000 description 1
- OUHPEQFMFIKJQZ-UHFFFAOYSA-N 3-aminopropyl carbamate Chemical compound NCCCOC(N)=O OUHPEQFMFIKJQZ-UHFFFAOYSA-N 0.000 description 1
- RITPLLYUVXGBFT-UHFFFAOYSA-N 4-methyl-1,2-oxazole-5-carboxylic acid Chemical compound CC=1C=NOC=1C(O)=O RITPLLYUVXGBFT-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 102000000079 Kainic Acid Receptors Human genes 0.000 description 1
- 108010069902 Kainic Acid Receptors Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- YKRSWMGPYKJOBF-UHFFFAOYSA-N [1-(4-chlorophenyl)-2-methylpropan-2-yl] 2-amino-3-methylbutanoate Chemical compound CC(C)C(N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1 YKRSWMGPYKJOBF-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940106135 cellulose Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000000718 cholinopositive effect Effects 0.000 description 1
- 231100000876 cognitive deterioration Toxicity 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 150000003950 cyclic amides Chemical class 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002260 hypophysiotrophic effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical class N1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- ONOUXANYVOEFTK-UHFFFAOYSA-N methyl sulfate;trimethyl-[4-(octadecanoylamino)phenyl]azanium Chemical compound COS([O-])(=O)=O.CCCCCCCCCCCCCCCCCC(=O)NC1=CC=C([N+](C)(C)C)C=C1 ONOUXANYVOEFTK-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- XEZLAJRZQNKEOJ-UHFFFAOYSA-N n-pentylhydroxylamine Chemical class CCCCCNO XEZLAJRZQNKEOJ-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940112042 peripherally acting choline derivative muscle relaxants Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GR99100005 | 1999-01-07 | ||
PCT/IB2000/000011 WO2000040244A1 (en) | 1999-01-07 | 2000-01-06 | Use of phanquinone for the treatment or prevention of memory impairment |
Publications (2)
Publication Number | Publication Date |
---|---|
IL143903A0 IL143903A0 (en) | 2002-04-21 |
IL143903A true IL143903A (en) | 2004-02-08 |
Family
ID=10943706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14390300A IL143903A (en) | 1999-01-07 | 2000-01-06 | A medicinal product containing pancovinone for the treatment or prevention of memory impairments |
Country Status (17)
Country | Link |
---|---|
US (1) | US7030136B2 (tr) |
EP (1) | EP1140090B1 (tr) |
JP (1) | JP2002534386A (tr) |
AR (1) | AR022215A1 (tr) |
AT (1) | ATE285235T1 (tr) |
AU (1) | AU1792200A (tr) |
BR (1) | BR0008241A (tr) |
CA (1) | CA2358487C (tr) |
DE (1) | DE60016892T2 (tr) |
DK (1) | DK1140090T3 (tr) |
ES (1) | ES2234559T3 (tr) |
HK (1) | HK1042039B (tr) |
IL (1) | IL143903A (tr) |
PT (1) | PT1140090E (tr) |
SI (1) | SI1140090T1 (tr) |
TR (1) | TR200101892T2 (tr) |
WO (1) | WO2000040244A1 (tr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU741782B2 (en) | 1997-08-21 | 2001-12-06 | P.N. Gerolymatos S.A. | Use of phanquinone for the treatment of Alzheimer's disease |
AU2001250573A1 (en) * | 2000-04-28 | 2001-11-12 | Michel Xilinas | Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using phanquinone |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1472257A (en) | 1973-09-10 | 1977-05-04 | Christiaens Sa A | Derivative of 4-hydroxy-5-azacoumarin |
DK662687A (da) * | 1986-12-17 | 1988-06-18 | Glaxo Group Ltd | Anvendelse af tricycliske carbazoloner |
US5091391A (en) * | 1990-08-16 | 1992-02-25 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of resisting neurodegenerative disorders |
EP0613560B2 (en) | 1991-11-12 | 2006-06-21 | Prana Biotechnology Ltd | A method for assaying and treating alzheimer's disease |
US5866597A (en) * | 1993-03-19 | 1999-02-02 | Glaxo Wellcome Inc. | Use of triazine compounds for the treatment of memory and learning disorders |
US5792774A (en) * | 1996-02-21 | 1998-08-11 | Chiroscience Limited | Quinolones and their therapeutic use |
AU1153097A (en) | 1996-06-07 | 1998-01-05 | Eisai Co. Ltd. | Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production |
EP0959888B1 (en) * | 1996-08-13 | 2001-09-05 | P.N. Gerolymatos S.A. | Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease |
WO1998040071A1 (en) | 1997-03-11 | 1998-09-17 | The General Hospital Corporation | Identification of agents for use in the treatment of alzheimer's disease |
AU741782B2 (en) * | 1997-08-21 | 2001-12-06 | P.N. Gerolymatos S.A. | Use of phanquinone for the treatment of Alzheimer's disease |
US5980914A (en) * | 1997-08-22 | 1999-11-09 | P.N. Gerolymatos S.A. | Clioquinol for the treatment of Parkinson's disease |
US5994323A (en) * | 1997-12-31 | 1999-11-30 | P.N. Gerolymatos S.A. | Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof |
-
2000
- 2000-01-06 AU AU17922/00A patent/AU1792200A/en not_active Abandoned
- 2000-01-06 ES ES00900025T patent/ES2234559T3/es not_active Expired - Lifetime
- 2000-01-06 CA CA002358487A patent/CA2358487C/en not_active Expired - Fee Related
- 2000-01-06 BR BR0008241-4A patent/BR0008241A/pt not_active Application Discontinuation
- 2000-01-06 EP EP00900025A patent/EP1140090B1/en not_active Expired - Lifetime
- 2000-01-06 AT AT00900025T patent/ATE285235T1/de not_active IP Right Cessation
- 2000-01-06 WO PCT/IB2000/000011 patent/WO2000040244A1/en not_active Application Discontinuation
- 2000-01-06 JP JP2000592001A patent/JP2002534386A/ja active Pending
- 2000-01-06 SI SI200030621T patent/SI1140090T1/xx unknown
- 2000-01-06 IL IL14390300A patent/IL143903A/en not_active IP Right Cessation
- 2000-01-06 AR ARP000100046A patent/AR022215A1/es unknown
- 2000-01-06 DK DK00900025T patent/DK1140090T3/da active
- 2000-01-06 PT PT00900025T patent/PT1140090E/pt unknown
- 2000-01-06 DE DE60016892T patent/DE60016892T2/de not_active Expired - Fee Related
- 2000-01-06 TR TR2001/01892T patent/TR200101892T2/tr unknown
-
2002
- 2002-03-15 US US10/098,922 patent/US7030136B2/en not_active Expired - Fee Related
- 2002-04-10 HK HK02102678.3A patent/HK1042039B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US20030055078A1 (en) | 2003-03-20 |
SI1140090T1 (en) | 2005-06-30 |
WO2000040244A1 (en) | 2000-07-13 |
AU1792200A (en) | 2000-07-24 |
AR022215A1 (es) | 2002-09-04 |
DE60016892D1 (de) | 2005-01-27 |
BR0008241A (pt) | 2001-10-30 |
IL143903A0 (en) | 2002-04-21 |
CA2358487C (en) | 2008-11-18 |
CA2358487A1 (en) | 2000-07-13 |
ES2234559T3 (es) | 2005-07-01 |
HK1042039B (zh) | 2005-07-29 |
JP2002534386A (ja) | 2002-10-15 |
US7030136B2 (en) | 2006-04-18 |
DE60016892T2 (de) | 2005-12-15 |
HK1042039A1 (en) | 2002-08-02 |
DK1140090T3 (da) | 2005-04-18 |
PT1140090E (pt) | 2005-05-31 |
ATE285235T1 (de) | 2005-01-15 |
EP1140090B1 (en) | 2004-12-22 |
EP1140090A1 (en) | 2001-10-10 |
TR200101892T2 (tr) | 2001-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0279114B1 (en) | Medicaments for the treatment or prevention of the withdrawal syndrome | |
JPH06508836A (ja) | 光学的に純粋なr(+)オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物 | |
JP2004512367A (ja) | 下肢静止不能症候群のための新しい療法 | |
CA2167004C (en) | Agent for treating mental disorders associated with cerebrovascular disorders | |
JP2022502479A (ja) | パーキンソン病および関連疾患の治療のための組成物および使用 | |
AU741782B2 (en) | Use of phanquinone for the treatment of Alzheimer's disease | |
AU2018219213A1 (en) | Treatment of diabetes and associated metabolic conditions with epigenetic modulators | |
CA2358487C (en) | Use of phanquinone for the treatment or prevention of memory impairment | |
WO2012077968A2 (en) | Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof | |
EP1061925B1 (en) | Combination of a gaba-a alpha 5 inverse agonist and a nicotinic agonist | |
CA1330536C (en) | Medicament for the treatment of a cognitive disorder | |
KR101016927B1 (ko) | 알츠하이머 질환의 치료용 nmda 길항제 및 아세틸콜린에스테라제 억제제의 조합물 | |
KR20030010740A (ko) | 신경변성 질환의 예방 및 치료약 | |
KR20010101399A (ko) | 기억 손상의 치료 또는 예방을 위한 판퀴논의 용도 | |
JPH11506096A (ja) | 認識機能不全を処置する方法 | |
JP3911392B2 (ja) | 脳血管障害に伴う精神症候の新規治療剤 | |
JPH02180822A (ja) | 医薬 | |
FR2916142A1 (fr) | Forme pharmaceutique comprenant du (10-[(3s)-1-azabicyclo [2.2.2]oct-3-ylmethyl]-10h-phenothiazine se presentant sous une forme appropriee pour l'administration d'unde dose journaliere comprise entre 1 et 3 mg | |
JP2006516596A (ja) | 偏頭痛の予防治療のためのカベルゴリン | |
FR2740343A1 (fr) | Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique | |
MXPA00001459A (en) | Use of phanquinone for the treatment of alzheimer's disease | |
JPH01250319A (ja) | 医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |